(Q37604549)

21 August 2017

Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy (English)

1 reference

21 August 2017

0 references

Jessica H Savage

1

1 reference

21 August 2017

Jean-Paul Courneya

2

1 reference

21 August 2017

Patricia M Sterba

3

1 reference

21 August 2017

Donald W Macglashan

4

1 reference

21 August 2017

Sarbjit S Saini

5

1 reference

21 August 2017

Robert A Wood

6

1 reference

21 August 2017

language of work or name

English

0 references

publication date

15 July 2012

1 reference

The Journal of Allergy and Clinical Immunology

21 August 2017

1 reference

21 August 2017

130

1 reference

21 August 2017

5

1 reference

21 August 2017

1123-1129.e2

1 reference

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Effect of anti-IgE therapy in patients with peanut allergy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Proposals for standardization of oral food challenge tests in infants and children

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Expression and modulation of FcepsilonRIalpha and FcepsilonRIbeta in human blood basophils

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

Spontaneous release of histamine from basophils and histamine-releasing factor in patients with atopic dermatitis and food hypersensitivity

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3935509

10.1016/J.JACI.2012.05.039

1 September 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

21 August 2017

1 reference